David A. Reardon, MD
Duke Health
8
8
8
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+1 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Kevin A camphausen, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Annick Desjardins, MD, FRCPC
Duke University
Shared therapeutic areas:
Worked with same sponsors:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Jaymes Holland
Alaunos Therapeutics
Shared therapeutic areas:
Thomas Kaley, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Katherine E Warren, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Daniel Landi, MD
Duke University
Shared therapeutic areas:
Worked with same sponsors:
Maryam Fouladi, MD
Nationwide Children's Hospital
Shared therapeutic areas:
Worked with same sponsors:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Sean Grimm, MD
Northwestern University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
Ph I SU011248 + Irinotecan in Treatment of Pts w MG
Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
All 8 trials loaded